Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

This study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1. After the initial randomized, 6-month double-blind, placebo-controlled period, participants who were initially assigned to placebo will receive a single-dose of YOLT-203 treatment whereas participants in the YOLT-203 group will receive a single-dose of placebo infusion.

Participants needed: 36
Trial details
Phase: Phase 2Age: 6+Biological sex: AllType: InterventionalSponsor: YolTech Therapeutics Co., LtdUpdated: May 14, 2026
Eligibility criteria

You are 6 years old or older. [+4]

You have signs that oxalate has affected parts of your body outside the kidneys. [+8]

Read more
Status: Recruiting

A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YOLT-201 in participants with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM).

Participants needed: 31
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: YolTech Therapeutics Co., LtdUpdated: Aug 6, 2024Locations: 3
Eligibility criteria

Age 18 - 80 years old (including the critical values), regardless of gender; [+22]

Amyloidosis is not caused by TTR protein, such as light chain amyloidosis; [+29]

Read more